Detail akcie Molecular Partn N online

Business Summary: Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Financial Summary: BRIEF: For the three months ended 31 March 2024, Molecular Partners AG revenues decreased 10% to SF2.7M. Net loss decreased 23% to SF11.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Net Foreign Exchange Gain increase from SF0K to SF3.4M (income), Selling/General/Admin Expense decrease of 17% to SF4.5M (expense).